Literature DB >> 16362318

Demarcation laser therapy in the management of macular-sparing persistent subretinal fluid after scleral buckling procedures.

Yew Meng Wong1, Noemi Lois.   

Abstract

BACKGROUND: Persistent or recurrent macular-sparing subretinal fluid (SRF) can sometimes occur following scleral buckling procedures. Observation and reoperation have been used in the management of such cases. Demarcation laser therapy (DLT) has been used to treat macular-sparing retinal detachments in the context of cytomegalovirus retinitis and as primary treatment for selected rhegmatogenous retinal detachments. There are, however, scarce data in the literature regarding its use following primary scleral buckling procedures. The current study explores the use of DLT under the latter circumstances.
METHODS: The medical records of all consecutive patients with persistent SRF sparing the macula following primary rhegmatogenous retinal detachment repair using a scleral buckling procedure were retrospectively reviewed. Only those patients in whom the breaks were localised to the area of indentation and, thus, seemed to be well supported by the buckle were included. Demographics, clinical characteristics of the retinal detachment prior to scleral buckling, extension of the residual SRF observed postoperatively, details of the laser procedure, anatomical and functional outcomes and complications were evaluated.
RESULTS: Seven patients, all females, with a mean age of 47.9 years (range: 20-81) were included in the study. The retinal detachments were superior (n=3), inferior (n=3) and subtotal, affecting both superior and inferior retina (n=1). Scleral buckling procedures were used to treat the retinal detachments in all cases. Following demarcation laser therapy, the area of SRF remained stable in two patients, and flattened in four. In one patient, extension of SRF occurred requiring further surgery.
CONCLUSIONS: Demarcation laser therapy appears to be a reasonable option in the management of patients with persistent or recurrent SRF sparing the macula following scleral buckling surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16362318     DOI: 10.1007/s00417-005-0165-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

Review 1.  Laser therapy for rhegmatogenous retinal detachment.

Authors:  P B Greenberg; C R Baumal
Journal:  Curr Opin Ophthalmol       Date:  2001-06       Impact factor: 3.761

2.  Laser photocoagulation repair of recurrent macula-sparing retinal detachments.

Authors:  Eun Suk Lee; Hyung Jun Koh; Oh Woong Kwon; Sung Chul Lee
Journal:  Yonsei Med J       Date:  2002-08       Impact factor: 2.759

3.  Pneumatic retinopexy as supplemental therapy for persistent retinal detachment after scleral buckling operation.

Authors:  H Levkovitch-Verbin; G Treister; J Moisseiev
Journal:  Acta Ophthalmol Scand       Date:  1998-06

4.  Early retinal adhesion from laser photocoagulation.

Authors:  J C Folk; S R Sneed; R Folberg; P Coonan; J S Pulido
Journal:  Ophthalmology       Date:  1989-10       Impact factor: 12.079

5.  Demarcation laser photocoagulation of selected macula-sparing rhegmatogenous retinal detachments.

Authors:  T R Vrabec; C R Baumal
Journal:  Ophthalmology       Date:  2000-06       Impact factor: 12.079

6.  Rapid enhancement of retinal adhesion by laser photocoagulation.

Authors:  Y H Yoon; M F Marmor
Journal:  Ophthalmology       Date:  1988-10       Impact factor: 12.079

7.  Laser photocoagulation for retinal detachments and retinal tears in cytomegalovirus retinitis.

Authors:  J L Davis; J Hummer; W J Feuer
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

8.  Laser photocoagulation repair of macula-sparing cytomegalovirus-related retinal detachment.

Authors:  T R Vrabec
Journal:  Ophthalmology       Date:  1997-12       Impact factor: 12.079

9.  Retinal detachments in patients with AIDS and CMV retinopathy: a role for laser photocoagulation.

Authors:  P McCluskey; J Grigg; T J Playfair
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.